Narudol Teerapattarakan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Narudol Teerapattarakan has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Shisanupong Anukanon
School of Medicine, Mae Fah Luang University, Muang, Chiang Rai 57100, Thailand
2 shared publications - Utcharaporn Kamsrijai
School of Medicine, Mae Fah Luang University, Chiang Rai 57100, Thailand
2 shared publications Gert Wohlgemuth
NIH West Coast Metabolomics Center, University of California Davis, CA, USA
1 shared publication- Hamid Rajabi
Unit of Innovative Food Packaging and Biomaterials, School of Agro-Industry, Mae Fah Luang University, Chiang Rai 57100, Thailand
1 shared publication Hattaya Benya-Aphikul
Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
1 shared publication- Marc Pignitter
Institute of Physiological Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 21 May 2026
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 7 (12) , 5937-5969
Multi-functional biomedical applications of nanoencapsulated herbal essential oils: polymer-based encapsulation strategies and key biological properties
This review explores polymer-based nanoencapsulation of herbal essential oils: delivery platforms, structure–function relations, and multi-functional biomedical applications.
- 21 May 2026
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 7 (12) , 5937-5969
Top Cited PapersOpen AccessMulti-functional biomedical applications of nanoencapsulated herbal essential oils: polymer-based encapsulation strategies and key biological properties
This review explores polymer-based nanoencapsulation of herbal essential oils: delivery platforms, structure–function relations, and multi-functional biomedical applications.
- Open Access
- 1 January 2025
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2025 (1) , 7334303
Tacca chantrieri André Rhizome Extract Alleviates Scopolamine‐Induced Cognitive Impairment and Neuroinflammation in Rats
Tacca chantrieri André is a native plant from Northern Thailand with reported pharmacological effects, including antioxidant, anti‐inflammatory, and neuroprotective properties. This study investigated the neuroinflammatory and cognitive‐enhancing effects of Tacca chantrieri André rhizome extract (TCE) in a scopolamine‐injected model, which mimics an Alzheimer’s disease (AD) animal model. Animals were divided into six groups: (1) a control group, (2) a vehicle‐treated group, (3) a donepezil‐treated group (3 mg/kg BW) as a positive control, and (4–6) three TCE‐treated groups receiving 50, 100, or 200 mg/kg BW once daily for 14 days. Starting on Day 8, animals received daily intraperitoneal injections of scopolamine (3 mg/kg BW) for 7 consecutive days to induce cognitive impairment. On day 14, behavioral tests were conducted, including the Y‐maze and open field tests. On day 15, animals were euthanized, and their brains were collected for Nissl staining, immunofluorescence staining, and biochemical analyses using an ELISA kit. Our results demonstrated that TCE treatment attenuated scopolamine‐induced memory deficits and neuroinflammation. Specifically, TCE administration reduced levels of proinflammatory cytokines, including tumor necrosis factor‐α (TNF‐α) and interleukin‐1β (IL‐1β), and decreased glial fibrillary acidic protein (GFAP) expression in the hippocampus. Additionally, TCE improved neuronal survival and enhanced serotonin levels, contributing to cognitive improvements. The qualitative analysis of TCE using LC‐QTOF‐MS identified various chemical constituents, including saponins, flavonoids, and phenolic compounds. These bioactive compounds contributed to the neuroprotective effects of TCE by modulating neuroinflammation and cognitive function. The neuroprotective effects of TCE suggested its potential as a therapeutic agent for memory impairment associated with AD.
- 1 January 2025
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2025 (1) , 7334303
Open AccessTacca chantrieri André Rhizome Extract Alleviates Scopolamine‐Induced Cognitive Impairment and Neuroinflammation in Rats
Tacca chantrieri André is a native plant from Northern Thailand with reported pharmacological effects, including antioxidant, anti‐inflammatory, and neuroprotective properties. This study investigated the neuroinflammatory and cognitive‐enhancing effects of Tacca chantrieri André rhizome extract (TCE) in a scopolamine‐injected model, which mimics an Alzheimer’s disease (AD) animal model. Animals were divided into six groups: (1) a control group, (2) a vehicle‐treated group, (3) a donepezil‐treated group (3 mg/kg BW) as a positive control, and (4–6) three TCE‐treated groups receiving 50, 100, or 200 mg/kg BW once daily for 14 days. Starting on Day 8, animals received daily intraperitoneal injections of scopolamine (3 mg/kg BW) for 7 consecutive days to induce cognitive impairment. On day 14, behavioral tests were conducted, including the Y‐maze and open field tests. On day 15, animals were euthanized, and their brains were collected for Nissl staining, immunofluorescence staining, and biochemical analyses using an ELISA kit. Our results demonstrated that TCE treatment attenuated scopolamine‐induced memory deficits and neuroinflammation. Specifically, TCE administration reduced levels of proinflammatory cytokines, including tumor necrosis factor‐α (TNF‐α) and interleukin‐1β (IL‐1β), and decreased glial fibrillary acidic protein (GFAP) expression in the hippocampus. Additionally, TCE improved neuronal survival and enhanced serotonin levels, contributing to cognitive improvements. The qualitative analysis of TCE using LC‐QTOF‐MS identified various chemical constituents, including saponins, flavonoids, and phenolic compounds. These bioactive compounds contributed to the neuroprotective effects of TCE by modulating neuroinflammation and cognitive function. The neuroprotective effects of TCE suggested its potential as a therapeutic agent for memory impairment associated with AD.
- Open Access
- 26 December 2024
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 5 (1) , 99-105
Polygonum odoratum Lour. Extract Attenuates Cytotoxicity and Suppresses Pro-inflammatory Gene Expression in Particulate Matter 10-induced Human Lung Cells
Particulate matter-10 (PM10) can penetrate the lungs, leading to increased lung cell injury and inflammation. The leaf extract of Polygonum odoratum Lour. (PO) is rich in quercetin, a compound known for its antioxidant and anti-inflammatory properties. This study aimed to evaluate the protective effect of PO in a PM10-induced human lung cell model. PM10 samples were collected in Chiang Rai, Thailand, and tested for cytotoxicity in the human lung epithelial cell line (A549). To assess the protective effect, cells were pre-treated with PO and subsequently exposed to PM10 (100 µg/mL) for 24 hours. Cell viability and lactate dehydrogenase (LDH) activity were measured, and the expression of pro-inflammatory genes, including interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-13 (IL-13), and interleukin-17 (IL-17), was analyzed using quantitative real-time polymerase chain reaction (RT-qPCR). The results demonstrated that PO attenuated PM10-induced lung cell injury in a dose-dependent manner and downregulated the mRNA expression of pro-inflammatory cytokines. In conclusion, PO shows potential as an alternative treatment for mitigating PM10-induced lung damage.
- 26 December 2024
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 5 (1) , 99-105
Open AccessPolygonum odoratum Lour. Extract Attenuates Cytotoxicity and Suppresses Pro-inflammatory Gene Expression in Particulate Matter 10-induced Human Lung Cells
Particulate matter-10 (PM10) can penetrate the lungs, leading to increased lung cell injury and inflammation. The leaf extract of Polygonum odoratum Lour. (PO) is rich in quercetin, a compound known for its antioxidant and anti-inflammatory properties. This study aimed to evaluate the protective effect of PO in a PM10-induced human lung cell model. PM10 samples were collected in Chiang Rai, Thailand, and tested for cytotoxicity in the human lung epithelial cell line (A549). To assess the protective effect, cells were pre-treated with PO and subsequently exposed to PM10 (100 µg/mL) for 24 hours. Cell viability and lactate dehydrogenase (LDH) activity were measured, and the expression of pro-inflammatory genes, including interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-13 (IL-13), and interleukin-17 (IL-17), was analyzed using quantitative real-time polymerase chain reaction (RT-qPCR). The results demonstrated that PO attenuated PM10-induced lung cell injury in a dose-dependent manner and downregulated the mRNA expression of pro-inflammatory cytokines. In conclusion, PO shows potential as an alternative treatment for mitigating PM10-induced lung damage.
- Open Access
- 2 November 2022
- Published by College of Graduate Studies, Walailak University in Trends in Sciences
- Vol. 19 (22) , 3918
Preliminary Computational Analysis of Pyrazinamide-Based Derivatives Reveals Possible Inhibition of SARS-CoV-2 RNA-Dependent RNA Polymerase, and Their Possible Use as Antiviral Agents
Pyrazinamide is a pyrazine analog currently used to treat tuberculosis. It shares a core structure similar to that of favipiravir, which is a promising drug candidate that may inhibit the SARS-CoV-2 RNA-dependent RNA polymerase. This feature could be an opportunity for further drug development of anti-COVID-19 medication starting from a pyrazinamide core structure. This study aimed to determine and predict the most effective pyrazinamide-based analogs against the SARS-CoV-2 RNA-dependent RNA polymerase by using combined ligand- and structure-based computational analysis. This study performed a rational in silico study to screen pyrazinamide-like molecules from a commercially available ZINC database, with a similarity score higher than 0.40, and then these screened for acceptable pharmacokinetic properties, and then to further conduct molecular docking analysis with SARS-CoV-2 RNA-dependent RNA polymerase. The results showed that compound 12, having a dichloropyrimidine core structure had a similarity score of 0.446. It exerted the most binding affinity with RNA-dependent RNA polymerase, with estimated docking scores of −5.72, −5.25, −7.06, −7.00 and −4.63 kcal/mol in intact, ribosylated, mono-phosphoribosylated, di-phosphoribosylated and tri-phosphoribosylated forms, respectively. Watson-Crick base-pairing of compound 12 indicated that it favored binding with the uracil nucleoside of the RNA template. Compound 12 was confirmed as the lead compound, being a pyrazinamide-like molecule, and so might be a most promising candidate molecule, as an adenine analog RNA-dependent RNA polymerase inhibitor. It is suggested that the antiviral effect of this lead compound should be studied further as part of a drug discovery and development process. HIGHLIGHTS In silico analysis was performed to screen pyrazinamide-like compounds against the RNA-dependent RNA polymerase Pharmacokinetics and drug-likeliness properties of fourteen preselected compounds were assessed by using SwissADME with favorable results Among these preselected compounds, compound 12 showed the best docking score in almost all of its phosphoribosylated forms GRAPHICAL ABSTRACT
- 2 November 2022
- Published by College of Graduate Studies, Walailak University in Trends in Sciences
- Vol. 19 (22) , 3918
Open AccessPreliminary Computational Analysis of Pyrazinamide-Based Derivatives Reveals Possible Inhibition of SARS-CoV-2 RNA-Dependent RNA Polymerase, and Their Possible Use as Antiviral Agents
Pyrazinamide is a pyrazine analog currently used to treat tuberculosis. It shares a core structure similar to that of favipiravir, which is a promising drug candidate that may inhibit the SARS-CoV-2 RNA-dependent RNA polymerase. This feature could be an opportunity for further drug development of anti-COVID-19 medication starting from a pyrazinamide core structure. This study aimed to determine and predict the most effective pyrazinamide-based analogs against the SARS-CoV-2 RNA-dependent RNA polymerase by using combined ligand- and structure-based computational analysis. This study performed a rational in silico study to screen pyrazinamide-like molecules from a commercially available ZINC database, with a similarity score higher than 0.40, and then these screened for acceptable pharmacokinetic properties, and then to further conduct molecular docking analysis with SARS-CoV-2 RNA-dependent RNA polymerase. The results showed that compound 12, having a dichloropyrimidine core structure had a similarity score of 0.446. It exerted the most binding affinity with RNA-dependent RNA polymerase, with estimated docking scores of −5.72, −5.25, −7.06, −7.00 and −4.63 kcal/mol in intact, ribosylated, mono-phosphoribosylated, di-phosphoribosylated and tri-phosphoribosylated forms, respectively. Watson-Crick base-pairing of compound 12 indicated that it favored binding with the uracil nucleoside of the RNA template. Compound 12 was confirmed as the lead compound, being a pyrazinamide-like molecule, and so might be a most promising candidate molecule, as an adenine analog RNA-dependent RNA polymerase inhibitor. It is suggested that the antiviral effect of this lead compound should be studied further as part of a drug discovery and development process. HIGHLIGHTS In silico analysis was performed to screen pyrazinamide-like compounds against the RNA-dependent RNA polymerase Pharmacokinetics and drug-likeliness properties of fourteen preselected compounds were assessed by using SwissADME with favorable results Among these preselected compounds, compound 12 showed the best docking score in almost all of its phosphoribosylated forms GRAPHICAL ABSTRACT
- 17 October 2018
- Published by Wiley in Biomedical Chromatography
- Vol. 33 (2) , e4395
Effects of Centella asiatica extract on antioxidant status and liver metabolome of rotenone‐treated rats using GC–MS
Centella asiatica has been used as a culinary vegetable or medicinal herb. In this study, the hepatoprotective effect of the standardized extract of C. asiatica (ECa233) in rotenone‐treated rats was examined using a GC–MS‐based metabolomic approach. ECa233 contains >80% triterpenoids with a ratio of madecassoside to asiaticoside of 1.5(±0.5):1. Rats were randomly divided into three groups (with six rats/group): sham negative control, rotenone positive control and the ECa233 test group. Rats in the ECa233 group received 10 mg/kg ECa233 orally for 20 days, followed by 2.5 mg/kg intraperitoneal rotenone injection to induce toxicity before being sacrificed. Metabolomic analysis showed that supplementation of ECa233 protected rat liver against rotenone toxicity. Pipecolinic acid was one of the most important metabolites; its level was decreased in the rotenone group as compared with the control. Supplementation with ECa233 before administration of rotenone raised pipecolinic acid to levels intermediate between controls and rotenone alone. The metabolomics approach also helped discover a possible new genuine epimetabolite in the present work. Antioxidant tests revealed that ECa233 inhibited lipid peroxidation and increased catalase activities in liver tissue.
- 17 October 2018
- Published by Wiley in Biomedical Chromatography
- Vol. 33 (2) , e4395
Effects of Centella asiatica extract on antioxidant status and liver metabolome of rotenone‐treated rats using GC–MS
Centella asiatica has been used as a culinary vegetable or medicinal herb. In this study, the hepatoprotective effect of the standardized extract of C. asiatica (ECa233) in rotenone‐treated rats was examined using a GC–MS‐based metabolomic approach. ECa233 contains >80% triterpenoids with a ratio of madecassoside to asiaticoside of 1.5(±0.5):1. Rats were randomly divided into three groups (with six rats/group): sham negative control, rotenone positive control and the ECa233 test group. Rats in the ECa233 group received 10 mg/kg ECa233 orally for 20 days, followed by 2.5 mg/kg intraperitoneal rotenone injection to induce toxicity before being sacrificed. Metabolomic analysis showed that supplementation of ECa233 protected rat liver against rotenone toxicity. Pipecolinic acid was one of the most important metabolites; its level was decreased in the rotenone group as compared with the control. Supplementation with ECa233 before administration of rotenone raised pipecolinic acid to levels intermediate between controls and rotenone alone. The metabolomics approach also helped discover a possible new genuine epimetabolite in the present work. Antioxidant tests revealed that ECa233 inhibited lipid peroxidation and increased catalase activities in liver tissue.
- 1 May 2018
- Published by Elsevier in Phytomedicine
- Vol. 44, 65-73
Neuroprotective effect of a standardized extract of Centella asiatica ECa233 in rotenone-induced parkinsonism rats
- 1 May 2018
- Published by Elsevier in Phytomedicine
- Vol. 44, 65-73
Neuroprotective effect of a standardized extract of Centella asiatica ECa233 in rotenone-induced parkinsonism rats